I have always wondered why other companies haven't tried to market it to date to phase 3.
There is a report dating back to 2005 Effects of pentosan polysulfate in osteoarthritis of the knee from Perth
It was a success back then so why did no one jump on it back then.
I realize that trials cost heaps of money and take time.
Another study back in 2010 Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis - An open clinical trial was a success from Japan I think so lots of info out there.
So my question is why did Paradigm jump on it and no one else?. As far as I know, Bene provides the injectable solution from their formula. Did paradigm change anything in the chemistry? Thanks for your insight Mozzarc.
PAR General discussion, page-3
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.015(7.50%) |
Mkt cap ! $75.30M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.5¢ | 20.0¢ | $175.5K | 833.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 8334 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |